| [1] |
Duijts SFA, van der Zwan JM. Rare cancers and cancer of unknown primary: here's what you should know![J]. Eur J Cancer Care (Engl), 2021, 30(6): e13508. DOI: 10.1111/ecc.13508.
|
| [2] |
Zhang S, He S, Zhu X, et al. DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffinem-bedded tissues[J]. Nat Commun, 2023, 14(1): 5686. DOI: 10. 1038/s41467-023-41015-0.
|
| [3] |
R Teixeira M, Oliveira J, Borralho P, et al. Portuguese consensus recommendations for next-generation sequencing of lung cancer, rare tumors, and cancers of unknown primary origin in clinical practice[J]. Acta Med Port, 2022, 35(9): 677-690. DOI: 10.20344/amp.17680.
pmid: 35816050
|
| [4] |
Liu X, Zhang X, Jiang S, et al. Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial[J]. Lancet Oncol, 2024, 25(8): 1092-1102. DOI: 10.1016/S1470-2045(24)00313-9.
|
| [5] |
Raghav K. Cancer of unknown primary site[J]. N Engl J Med, 2025, 392(20): 2035-2047. DOI: 10.1056/NEJMcp2402691.
|
| [6] |
Lazaridis G, Pentheroudakis G, Fountzilas G, et al. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature[J]. Cancer Treat Rev, 2008, 34(8): 693-700. DOI: 10.1016/j.ctrv.2008.05.005.
pmid: 18584969
|
| [7] |
Lammert A, Abo-Madyan Y, Huber L, et al. Zervikales CUP-syndrome: diagnostik and therapie[J]. Laryngorhinootologie, 2024, 103(5): 371-382. DOI: 10.1055/a-2150-4834.
pmid: 38697084
|
| [8] |
Bochtler T, Pouyiourou M, Krämer A. Cancer of unknown primary-the new ESMO guidelines[J]. Radiologie (Heidelb), 2023, 63(5): 329-335. DOI: 10.1007/s00117-023-01126-7.
|
| [9] |
van der Strate I, Kazemzadeh F, Nagtegaal ID, et al. International consensus on the initial diagnostic workup of cancer of unknown primary[J]. Crit Rev Oncol Hematol, 2023, 181: 103868. DOI: 10. 1016/j.critrevonc.2022.103868.
|
| [10] |
Krämer A, Bochtler T, Pauli C, et al. Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(3): 228-246. DOI: 10.1016/j.annonc.2022.11.013.
|
| [11] |
Krämer A, Bochtler T, Pauli C, et al. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study[J]. Lancet, 2024, 404(10452): 527-539. DOI: 10.1016/S0140-6736(24)00814-6.
pmid: 39096924
|
| [12] |
Khosravi GR, Mostafavi S, Bastan S, et al. Immunologic tumor microenvironment modulators for turning cold tumors hot[J]. Cancer Commun (Lond), 2024, 44(5): 521-553. DOI: 10.1002/cac2.12539.
|
| [13] |
McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future[J]. Cell, 2017, 168(4): 613-628. DOI: 10.1016/j.cell.2017.01.018.
pmid: 28187284
|
| [14] |
Cascone SA, Heymach JV. Chemotherapy and immunotherapy: a winning combination?[J]. Nat Rev Clin Oncol, 2021, 18(12): 721-738. DOI: 10.1038/s41571-021-00537-2.
|
| [15] |
Yap TA, Parkes EE, Peng W, et al. Development of immunotherapy combination strategies in cancer[J]. Cancer Discov, 2021, 11(6): 1368-1397. DOI: 10.1158/2159-8290.CD-20-1209.
pmid: 33811048
|
| [16] |
Kuwano A, Yoshikai M, Ohtsubo S, et al. Effectiveness of surgery and chemotherapy with immune checkpoint inhibitor for cardiac metastatic squamous cell carcinoma of unknown primary[J]. J Cardiol Cases, 2024, 1531(2): 39-41. DOI: 10.1016/j.jccase.2024.10.002.
|
